Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “warfarin sodium” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 2
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 2 pipeline programs matching "warfarin sodium" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

2 results for “warfarin sodium” Back to intelligence hub

Search results

  1. Warfarin Sodium

    Hospital Authority, Hong Kong

    Indications for Warfarin Therapy

    phase 3 small molecule active

    1 trial
  2. warfarin sodium

    IONIS PHARMACEUTICALS INC

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.